Investigating how certain proteins affect the entry of New World Arenaviruses into cells
The role of TRIM2 and SIRPA in New World Arenavirus entry
This study is looking at how certain viruses, like the Junín virus that causes hemorrhagic fever, get into human cells and make us sick, and it's trying to find ways to block that entry to help create better treatments or vaccines for people affected by these viruses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11075351 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms by which New World hemorrhagic fever arenaviruses, such as the Junín virus, enter human cells and cause disease. The study aims to identify host proteins that can block this viral entry, which could lead to new therapeutic targets. By using advanced techniques like siRNA screening, researchers are exploring the role of proteins like TRIM2 in the viral infection process. This could help in developing effective treatments or vaccines for these dangerous viruses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of exposure to New World Arenaviruses, particularly those in endemic regions or with occupational exposure.
Not a fit: Patients who are not at risk of exposure to New World Arenaviruses or those who have already been vaccinated against these viruses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies or vaccines that significantly reduce the mortality and morbidity associated with New World Arenavirus infections.
How similar studies have performed: Other research has shown promise in identifying host factors that influence viral entry, suggesting that this approach could yield valuable insights.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Ross, Susan R — University of Illinois at Chicago
- Study coordinator: Ross, Susan R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.